188 related articles for article (PubMed ID: 16627375)
1. An update on the Diabetes Prevention Program.
Ratner RE;
Endocr Pract; 2006; 12 Suppl 1(Suppl 1):20-4. PubMed ID: 16627375
[TBL] [Abstract][Full Text] [Related]
2. [Progress in the prevention of type 2 diabetes].
Schernthaner G
Wien Klin Wochenschr; 2003 Nov; 115(21-22):745-57. PubMed ID: 14743578
[TBL] [Abstract][Full Text] [Related]
3. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.
Knowler WC; Hamman RF; Edelstein SL; Barrett-Connor E; Ehrmann DA; Walker EA; Fowler SE; Nathan DM; Kahn SE;
Diabetes; 2005 Apr; 54(4):1150-6. PubMed ID: 15793255
[TBL] [Abstract][Full Text] [Related]
4. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
Flórez H
Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
[TBL] [Abstract][Full Text] [Related]
5. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
; Knowler WC; Fowler SE; Hamman RF; Christophi CA; Hoffman HJ; Brenneman AT; Brown-Friday JO; Goldberg R; Venditti E; Nathan DM
Lancet; 2009 Nov; 374(9702):1677-86. PubMed ID: 19878986
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
[TBL] [Abstract][Full Text] [Related]
7. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Ratner RE; Christophi CA; Metzger BE; Dabelea D; Bennett PH; Pi-Sunyer X; Fowler S; Kahn SE;
J Clin Endocrinol Metab; 2008 Dec; 93(12):4774-9. PubMed ID: 18826999
[TBL] [Abstract][Full Text] [Related]
8. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
The Diabetes Prevention Program Research Group
Diabetes Care; 1999 Apr; 22(4):623-34. PubMed ID: 10189543
[TBL] [Abstract][Full Text] [Related]
9. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom.
Palmer AJ; Roze S; Valentine WJ; Spinas GA; Shaw JE; Zimmet PZ
Clin Ther; 2004 Feb; 26(2):304-21. PubMed ID: 15038953
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
Diabetes Prevention Program Research Group
Lancet Diabetes Endocrinol; 2015 Nov; 3(11):866-75. PubMed ID: 26377054
[TBL] [Abstract][Full Text] [Related]
11. First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes.
Venditti EM; Bray GA; Carrion-Petersen ML; Delahanty LM; Edelstein SL; Hamman RF; Hoskin MA; Knowler WC; Ma Y;
Int J Obes (Lond); 2008 Oct; 32(10):1537-44. PubMed ID: 18711387
[TBL] [Abstract][Full Text] [Related]
12. Background and recruitment data for the U.S. Diabetes Prevention Program.
Fujimoto WY;
Diabetes Care; 2000 Apr; 23 Suppl 2(Suppl 2):B11-3. PubMed ID: 10860185
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study.
Herman WH
Clin Diabetes Endocrinol; 2015; 1():9. PubMed ID: 28702228
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
Eddy DM; Schlessinger L; Kahn R
Ann Intern Med; 2005 Aug; 143(4):251-64. PubMed ID: 16103469
[TBL] [Abstract][Full Text] [Related]
15. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.
Diabetes Prevention Program Research Group
Diabetes Care; 2003 Sep; 26(9):2518-23. PubMed ID: 12941712
[TBL] [Abstract][Full Text] [Related]
16. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.
Aroda VR; Christophi CA; Edelstein SL; Zhang P; Herman WH; Barrett-Connor E; Delahanty LM; Montez MG; Ackermann RT; Zhuo X; Knowler WC; Ratner RE;
J Clin Endocrinol Metab; 2015 Apr; 100(4):1646-53. PubMed ID: 25706240
[TBL] [Abstract][Full Text] [Related]
17. The changing cost to prevent diabetes: A retrospective analysis of the Diabetes Prevention Program.
Carris NW; Cheng F; Kelly WN
J Am Pharm Assoc (2003); 2017; 57(6):717-722. PubMed ID: 28807660
[TBL] [Abstract][Full Text] [Related]
18. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
Ratner R; Goldberg R; Haffner S; Marcovina S; Orchard T; Fowler S; Temprosa M;
Diabetes Care; 2005 Apr; 28(4):888-94. PubMed ID: 15793191
[TBL] [Abstract][Full Text] [Related]
19. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.
Aroda VR; Knowler WC; Crandall JP; Perreault L; Edelstein SL; Jeffries SL; Molitch ME; Pi-Sunyer X; Darwin C; Heckman-Stoddard BM; Temprosa M; Kahn SE; Nathan DM;
Diabetologia; 2017 Sep; 60(9):1601-1611. PubMed ID: 28770322
[TBL] [Abstract][Full Text] [Related]
20. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program.
Hernan WH; Brandle M; Zhang P; Williamson DF; Matulik MJ; Ratner RE; Lachin JM; Engelgau MM;
Diabetes Care; 2003 Jan; 26(1):36-47. PubMed ID: 12502656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
